$RDHL

Very critical month (November 2):

Key Highlights and Upcoming Milestones:

U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori
for priority review and assignment of a target PDUFA action date of November 2,
2019
• Preparations ongoing for the potential U.S. commercial launch of Talicia® in Q4/2019,
subject to FDA approval, with RedHill’s established sales force, led by the Company’s
experienced commercial management team
• FDA meetings planned to take place in H2/2019 to discuss the path to potential
approval of RHB-104 for Crohn’s disease
• Initiation of pivotal Phase 3 study activities with RHB-204 for first-line treatment of
pulmonary nontuberculous mycobacteria (NTM) infections expected in Q4/2019
• Debt-free balance sheet with $34.9 million cash balance as of June 30, 2019

All of the above at your discretion, your accepted trading rules, trading strategies and your preferred trading management.
This is not a recommendation to buy or sell.